Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

Authors Yawn BP, Li YF, Tian HJ, Zhang J, Arcona S, Kahler KH

Received 5 January 2013

Accepted for publication 22 March 2013

Published 27 June 2013 Volume 2013:8 Pages 295—304


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Barbara P Yawn,1 Yunfeng Li,2 Haijun Tian,2 Jie Zhang,2 Steve Arcona,2 Kristijan H Kahler2

1Department of Research, Olmsted Medical Center, Rochester, MN, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Background: The use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of pneumonia in controlled clinical trials and case-control analyses.
Objective: Using claims databases as a research model of real-world diagnosis and treatment, to determine if the use and dose of inhaled corticosteroids (ICS) among patients with newly diagnosed COPD are associated with increased risk of pneumonia.
Patients and methods: This was a retrospective cohort analysis of patients diagnosed with COPD between January 01, 2006 and September 30, 2010, drawn from databases (years 2006–2010). Patients (aged ≥45 years) were followed until first pneumonia diagnosis, end of benefit enrollment, or December 31, 2010, whichever was earliest. A Cox proportional hazard model was used to assess the association of ICS use and risk of pneumonia, controlling for baseline characteristics. Daily ICS use was classified into low, medium, and high doses (1 µg–499 µg, 500 µg–999 µg, and ≥1000 µg fluticasone equivalents daily) and was modeled as a time-dependent variable.
Results: Among 135,445 qualifying patients with a total of 243,097 person-years, there were 1020 pneumonia incidences out of 5677 person-years on ICS (crude incidence rate, 0.180 per person-year), and 27,730 pneumonia incidences out of 237,420 person-years not on ICS (crude incidence rate, 0.117 per person-year). ICS use was associated with a dose-related increase in risk of pneumonia, with adjusted hazard ratios (versus no use; (95% confidence interval) of 1.38 (1.27–1.49) for low-dose users, 1.69 (1.52–1.88) for medium-dose users, and 2.57 (1.98–3.33) for high-dose users (P < 0.01 versus no use and between doses).
Conclusion: The use of ICS in newly diagnosed patients with COPD is potentially associated with a dose-related increase in the risk of pneumonia.

Keywords: COPD, ICS, LABA, pneumonia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

Protocol for the asthma tools study: a pragmatic practice-based research network trial

Yawn BP, Bertram S, Kurland M, Wollan P, Graham D, Littlefield D, Smail C, Pace W

Pragmatic and Observational Research 2013, 4:7-18

Published Date: 4 June 2013

Exacerbations in the pre- and post-COPD diagnosis periods

Yawn BP, Wollan P, Rank M

Pragmatic and Observational Research 2013, 4:1-6

Published Date: 2 May 2013

Automated patient and medication payment method for clinical trials

Yawn BP, Madison S, Bertram S, Pace WD, Fuhlbrigge A, Israel E, Littlefield D, Kurland M, Wechsler ME

Open Access Journal of Clinical Trials 2013, 5:23-31

Published Date: 29 January 2013

Introduction of Asthma APGAR tools improve asthma management in primary care practices

Barbara P Yawn, Susan Bertram, Peter Wollan

Journal of Asthma and Allergy 2008, 1:1-10

Published Date: 31 August 2008

Readers of this article also read:

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma

Wei MY, Guo XC, Tu LX, Zou Q, Li Q, Tang CY, Chen B, Xu YH, Wu CB

International Journal of Nanomedicine 2015, 10:5123-5137

Published Date: 12 August 2015

Blood group antigen studies using CdTe quantum dots and flow cytometry

Cabral Filho PE, Pereira MIA, Fernandes HP, de Thomaz AA, Cesar CL, Santos BS, Barjas-Castro ML, Fontes A

International Journal of Nanomedicine 2015, 10:4393-4404

Published Date: 8 July 2015

Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits

Chang CH, Tsao KC, Hu HC, Huang CC, Kao KC, Chen NH, Yang CT, Tsai YH, Hsieh MJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:767-774

Published Date: 13 April 2015

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

Specific targeting of A54 homing peptide-functionalized dextran-g-poly(lactic-co-glycolic acid) micelles to tumor cells

Situ JQ, Ye YQ, Zhu XL, Yu RS, You J, Yuan H, Hu FQ, Du YZ

International Journal of Nanomedicine 2015, 10:665-675

Published Date: 17 January 2015

Surface treatment of silica nanoparticles for stable and charge-controlled colloidal silica

Kim KM, Kim HM, Lee WJ, Lee CW, Kim TI, Lee JK, Jeong J, Paek SM, Oh JM

International Journal of Nanomedicine 2014, 9:29-40

Published Date: 15 December 2014

Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease

Ito K, Colley T, Mercado N

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:641-652

Published Date: 21 September 2012